Should we routinely use mupirocin to prevent staphylococcal infections?
Routine use of mupirocin to prevent staphylococcal infections is controversial. We assessed attitudes and practices of healthcare professionals attending the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections regarding mupirocin prophylaxis. Eighty percent of participants did not use mupirocin routinely. At the end of the session, 58% indicated they would consider increased use of mupirocin.
Roth
V R
VR
Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Public Health Service, United States Department of Health and Human Services, Atlanta, Georgia, USA.
Murphy
C
C
Perl
T M
TM
DeMaria
A
A
Sohn
A H
AH
Sinkowitz-Cochran
R L
RL
Jarvis
W R
WR
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D003428:Cross Infection / Q000517:prevention & control*; D006801:Humans; D016712:Mupirocin / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity
D000900:Anti-Bacterial Agents; D016712:Mupirocin